

(19) DANMARK

(10) DK/EP 2734842 T3



(12)

Oversættelse af
europæisk patent

Patent- og
Varemærkestyrelsen

(51) Int.Cl.: **G 01 N 33/543 (2006.01)** **G 01 N 33/558 (2006.01)**

(45) Oversættelsen bekendtgjort den: **2016-04-11**

(80) Dato for Den Europæiske Patentmyndigheds
bekendtgørelse om meddelelse af patentet: **2016-01-20**

(86) Europæisk ansøgning nr.: **12738592.0**

(86) Europæisk indleveringsdag: **2012-07-19**

(87) Den europæiske ansøgnings publiceringsdag: **2014-05-28**

(86) International ansøgning nr.: **GB2012051733**

(87) Internationalt publikationsnr.: **WO2013011323**

(30) Prioritet: **2011-07-19 GB 201112395**

(84) Designerede stater: **AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Patenthaver: **The Bio Nano Centre Limited, The Gridiron Building , One Pancras Square, London, N1C 4AG, Storbritannien**

(72) Opfinder: **CASS, Anthony Edward George, Bio Nano Consulting, 338 Euston Road, London NW1 3BT, Storbritannien**
REHAK, Marian, Bio Nano Consulting, 338 Euston Road, London NW1 3BT, Storbritannien
CELAYA SANFIZ, Almudena, Bio Nano Consulting, 338 Euston Road, London NW1 3BT, Storbritannien

(74) Fuldmægtig i Danmark: **Plougmann Vingtoft A/S, Rued Langgaards Vej 8, 2300 København S, Danmark**

(54) Benævnelse: **APPARAT OG FREMGANGSMÅDE TIL LATERALE FLOW-AFFINITETS-ASSAY**

(56) Fremdragne publikationer:
US-A1- 2003 077 642
US-A1- 2005 170 405

DK/EP 2734842 T3

DESCRIPTION

Background

[0001] Affinity assays are widely used in medical, food, and environmental research and are based on the principle of a reagent binding to a target analyte. The binding interaction is detected through some physico-chemical change, the magnitude of which is proportional to the analyte concentration. Many different reagents have been described including, but not limited to, antibodies, other proteins, nucleic acids, and synthetic receptors.

[0002] Antibodies are commonly used as the reagent and many different assay formats using antibodies have been described. These are collectively referred to as immunoassays. One type of immunoassay which is particularly suitable for point of care tests (POCTs) is the lateral flow (LF) immunoassay (also referred to as an immunochromatographic assay).

[0003] LF immunoassays are a well-established and robust technology for detection of antigens. They are adapted to operate along a single axis to suit a test strip format and typically employ a sandwich (also referred to as 2-site, reagent excess or non-competitive) format. In this format one of two antibodies is labelled, typically with coloured particles, and dried as a soluble preparation on a LF membrane (typically a hydrophobic nitrocellulose or cellulose acetate membrane). This first antibody dissolves in the sample, whilst a second antibody is fixed to the LF membrane some short distance from the first antibody. Sample solution carries the first antibody to the second through capillary flow and the immune complex that forms during this flow is captured by the second antibody forming a visible line. Excess labelled first antibody is carried past this 'test line' to react at a control line. This provides a qualitative read-out.

[0004] More recently the format has been modified such that the second antibody, labelled with biotin, is also soluble and the sandwich complex is formed in solution during the LF before being captured at a streptavidin line. US2010/0267166 describes a device for detecting an analyte, comprising a labelled conjugate comprising a binding member reacted with a first epitope of the analyte and a label, and a biotinylated capture component having a site reactive with a second epitope of the analyte.

[0005] It would be advantageous to adapt this assay format further, in order to increase its sensitivity and provide a quantitative numerical readout of the amount of immune complex at the second line, whilst retaining the essential simplicity and robustness of the LF format.

Summary of the Invention

[0006] According to a first aspect of the invention, apparatus for the quantitative analysis of an analyte in a sample comprises:

1. (i) solid phase; and
2. (ii) a detector,

wherein the surface of the solid phase comprises:

1. (a) a first position for sample application; and
2. (b) a second position distant from the first position,

wherein a first molecule that binds to the analyte and is capable of releasing a detectable species is either deposited on the solid phase or is added to the sample prior to application to the solid phase, and

wherein a second molecule that binds to the analyte is immobilised at the second position, and

wherein an enzyme is immobilised, co-located with the immobilised molecule at the second position, and

wherein the detector is located in close proximity to the immobilised molecule at the second position.

[0007] According to a second aspect of the invention, a method for quantitative detection of target molecules in a substrate-containing sample comprises:

1. a) dissolving a first soluble labelled binding molecule that is capable of releasing a detectable species and a second soluble labelled binding molecule in the sample to form a complex;
2. b) applying the complex formed in step a) to a solid phase, wherein the surface of the solid phase comprises:
 1. i) a first position for application of the complex; and

2. ii) a second position, distant from the first position
wherein a molecule that binds to the second labelled binding molecule is immobilised at the second position, wherein an enzyme is immobilised co-located with the immobilised molecule at the second position, and wherein a detector is located in close proximity to the immobilised molecule at the second position; and
3. c) detecting the detectable species at the detector,

wherein detection of said species is proportional to the target molecule content of the sample.

[0008] According to a third aspect of the invention, the apparatus described in the first aspect of the invention is used in the method for quantitative detection of target molecules in a substrate-containing sample according to the second aspect of the invention.

Description of the Drawings

[0009]

Figure 1 is a schematic representation of the amplified electrochemical lateral flow (LF) test strip;

Figure 2 is a schematic representation of the amplified electrochemical reaction;

Figure 3 is a graphical representation of the pH change as a function of the enzymatic reaction between urease and urea in a 2mM Tris/HCl buffer solution;

Figure 4 is a graphical representation of the pH change as a function of the enzymatic reaction between pyrophosphate and pyrophosphatase in a solution with a low buffering capacity (2mM Tris/HCl buffer with addition of 2mM MgCl₂);

Figure 5 is a graph showing the effect of increasing the local pH on release of a first encapsulated label;

Figure 6 shows a similar effect to Figure 5 but using potassium ferricyanate as the first label rather than ferrocene carboxylic acid; and

Figure 7 shows the production of current as a function of ferrocene carboxylic acid release from polymeric bead at different time points.

Detailed Description of the Invention

[0010] The present invention addresses the aims of increasing the sensitivity of binding assays and is described in detail with reference to the lateral flow (LF) immunoassay. The invention provides a quantitative numerical readout of the amount of immune complex present in a sample, whilst retaining the simplicity and robustness of the assay format, by replacing the visual estimation of immune complex formation with an electrochemical measurement.

[0011] This is achieved, for example, by labeling one of two binding molecules, which may be antibodies, with particles that function as a source of a redox reagent that is detected at the test line. However, other approaches are also effective and these include, but are not limited to: encapsulated surface enhanced resonance Raman scattering (SERRS) active dyes; encapsulated mixture of a fluorescent molecule and a quencher; and encapsulated luciferase substrate to produce light emission at the test line. Therefore, although the invention is illustrated with respect to lateral flow assays, the scope of the invention is not limited to either the lateral flow assay format or to the antibody-antigen interaction detection.

[0012] According to a first aspect, the invention provides an apparatus for the quantitative analysis of an analyte in a sample, comprising:

1. (i) solid phase; and
2. (ii) a detector,

wherein the surface of the solid phase comprises:

1. (a) a first position for sample application; and

2. (b) a second position, distant from the first position,

wherein a first molecule that binds to the analyte and is capable of releasing a detectable species is either deposited on the solid phase or is added to the sample prior to application to the solid phase, and
 wherein a second molecule that binds to the analyte is immobilised at the second position, and
 wherein an enzyme is immobilised, co-located with the immobilised molecule at the second position, and
 wherein the detector is located in close proximity to the immobilised molecule at the second position.

[0013] As used herein, the term "distant from" means that the second position is not immediately adjacent to the first position. Preferably, the second position is located downstream from the first position in the direct of flow.

[0014] As used herein, the term "close proximity" means that the detector must be positioned sufficiently close to the immobilized molecule at the second position to be able to detect any change in current or charge passed at said second position. Preferably, the detector is located as close as possible to the immobilized molecule at the second position.

[0015] The solid phase may be any suitable solid material or membrane, such as porous and/or non-porous surfaces such as silicon, silicon oxide, metallic and metal-coated surfaces, polymeric and polysaccharide surfaces. Preferably, the solid phase is a lateral flow (LF) membrane, preferably comprising chromatogenic media, which may be polymeric or cellulosic, such as hydrophobic nitrocellulose or cellulose acetate.

[0016] According to a second aspect, the present invention also provides a method for quantitative detection of target molecules in a substrate-containing sample. The method comprises the following steps:

1. a) dissolving a first soluble labelled binding molecule that is capable of releasing a detectable species and a second soluble labelled binding molecule in the sample to form a complex;

2. b) applying the complex formed in step a) to a solid phase, wherein the surface of the solid phase comprises:

1. i) a first position for application of the complex; and
2. ii) a second position distant from the first position

wherein a molecule that binds to the second labelled binding molecule is immobilised at the second position, wherein an enzyme is immobilised co-located with the immobilised molecule at the second position, and wherein a detector is located in close proximity to the immobilised molecule at the second position; and

3. c) detecting the detectable species at the detector,

wherein detection of said species is proportional to the target molecule content of the sample.

[0017] Preferably, the target molecule is an antigen and the first and second labelled binding molecules are antibodies. In such an embodiment, the complex formed is an immune complex.

[0018] Step (c) may take place as the complex is transported to the second position. Such transportation may be by means of capillary action, microfluidics or electrophoretic migration.

[0019] The apparatus described in the first aspect of the invention can be used in the method for quantitative detection of target molecules in a substrate-containing sample according to the second aspect of the invention.

[0020] The apparatus and method of the invention are exemplified by the combinations of enzyme and substrate shown in Table 1. However, many other combinations are also within the scope of the invention and would be apparent to one skilled in the art of enzymology.

Table 1

Enzyme	Substrate
Urease	Urea
Glucose Oxidase	Glucose
Pyrophosphatase	Pyrophosphate
Alkaline phosphatase	Phenylphosphate
β -lactamase	Penicillin

[0021] The method utilises the presence of substrate in the sample to change the local pH at the test line through the co-

deposition of a corresponding enzyme immobilized at the second position. As would be understood by a person skilled in the art, the term "corresponding enzyme" to refer to an entity that catalysis the chemical reaction with a given substrate. Examples of compositions of the immune complexes that are applied to the solid phase membrane and the test line (i.e. the second position) are illustrated schematically in Figure 1.

[0022] The first label that is capable of releasing a detectable species is preferably a redox probe, and is preferably encapsulated in a polymer. The polymer may be an enteric coating material which dissolves when subjected to a pH change, typically under alkaline conditions, or alternatively it may be a 'smart' stimuli responsive polymer that swells in response to a pH change.

[0023] Suitable enteric polymers include polyvinyl acetate phthalate, hydroxypropyl methylcellulose phthalate, methacrylic acid, cellulose acetate trimellitate, carboxymethyl ethylcellulose and hydroxypropyl methylcellulose acetate succinate.

[0024] Suitable pH-responsive 'smart' polymers include poly(propylacrylic acid) and chitosan.

[0025] Suitable redox probes undergo fast, preferably diffusion-limited, electron exchange at the detector and include complexes of iron, osmium, copper and ruthenium, as well as organic molecules such as flavins and dyes. Specific examples include but are not limited to: ferrocene and its derivatives; iron complexes such as hexacyanide; ruthenium complexes such as hexamine; osmium complexes as tris(bipyridyl); thiazine dyes; phenazine dyes; riboflavin and its derivatives; and tetrathiafulvalene and its derivatives. Additional examples will be apparent to those skilled in the art.

[0026] The second binding molecule is preferably labelled with biotin and the molecule that binds to it, and which is immobilised at the second position, is preferably avidin or streptavidin.

[0027] The detector located in close proximity to the immobilised molecule at the second position is preferably positioned below the test line (i.e. at or underneath the second position on the LF membrane). The detector is preferably an electrode, and preferably a screen printed electrode. The skilled person will be familiar with the term "screen-printed electrode". However, for the avoidance of doubt, this is defined as a conducting carbon ink or metal paste film deposited on an inert support, such as PVC, ceramic, and alumina or polyester, and incorporating reference and counter electrodes. The electrode is preferably poised at a potential where there is a diffusion-limited reduction of the redox probe and a minimal background current from the sample. The detector must be positioned in sufficiently close proximity to the immobilized molecule at the second position (i.e. the test line) to be able to detect the change in current or charge passed.

[0028] The apparatus and method of the invention may be used for the *in vitro* quantitative analysis of many analytes including antigens, antibodies, other proteins and the products of nucleic acid amplification tests. The test sample may be selected from the following non-limiting group of body samples obtained from a subject or patient: urine; saliva; serum; plasma; whole blood; faeces; and exudates (e.g. from wounds or lesions). Alternatively, the sample may be a non-clinical material, such as soil, air, water or food matter.

[0029] The apparatus and method of the invention can be used as a tool to aid diagnosis and patient management. For example, the assay can be used to identify, confirm, or rule out disease in symptomatic patients, or to accurately prescribe therapeutic drugs and to monitor treatment, for example to monitor blood sugar levels in diabetic patients or to determine pregnancy. Other uses also include in epidemiology, where the rapid assay can be used to detect and monitor the incidence or prevalence of disease for targeting and evaluating health programs, as well as in screening to determine the prevalence of disease in asymptomatic individuals.

[0030] The terms 'subject' and 'patient' are used interchangeably herein and refer to a mammal including a non-primate (e.g. a cow, pig, horse, dog, cat, rat and mouse) and a primate (e.g. a monkey and human), and preferably a human.

[0031] By way of example, we illustrate an embodiment of the invention as a lateral flow immunoassay wherein the first and second binding molecules are antibodies, the target analyte is an antigen and the solid phase is a lateral flow membrane.

[0032] Upon addition of the substrate-containing sample, the two antibodies dissolve and form the immune complex which is carried by lateral flow to the test line. The immune complex travels with the liquid front and is captured at the test line by the reaction between the biotin component of the immune complex and avidin/streptavidin present in the test line. Once the substrate arrives at the test line there is a local change in pH due to the conversion of the substrate within the test sample. This may be a change to a more acidic environment (i.e. a decrease in pH) to a more alkaline environment (i.e. an increase in pH) depending upon the specific enzyme used.

[0033] The amplified electrochemical reaction that takes place at the test line is illustrated schematically in Figure 2.

[0034] In one embodiment, the substrate-containing sample is preferably urine and the corresponding enzyme is therefore preferably urease. The concentration of urea in urine is around 10-20 times the Km value for urease; therefore the enzyme will be running at its maximal rate. The change in pH results in the redox probe undergoing reduction and releasing the redox species, which is detected from the current (or charge passed) at the underlying electrode. The current resulting from the released redox species is proportional to the antigen content of the sample. Therefore, by measuring the current (or charge passed) at the electrode, the antigen content of the sample can be determined quantitatively. Figure 3 illustrates the pH change as a function of the enzymatic reaction between urease and urea in a solution with a low buffering capacity (2mM Tris/HCl buffer).

[0035] Alternatively, the substrate-containing sample may be pyrophosphate and the corresponding enzyme is therefore preferably pyrophosphatase. Figure 4 illustrates the pH change as a function of the enzymatic reaction between pyrophosphate and pyrophosphatase in a solution with a low buffering capacity (2mM Tris/HCl buffer with addition of 2mM MgCl₂).

[0036] The effect of increasing the local pH on release of the first encapsulated label (a redox probe, specifically a ferrocene derivative) is illustrated in Figure 5. This graph shows the spectrophotometric determination of ferrocene carboxylic acid release from polymeric beads as a function of time, at an alkaline pH of 9. As can be seen from the control values, when the pH is maintained at a mildly acidic pH of 5 the polymer does not dissolve and there is no increase in absorbance.

[0037] Figure 6 illustrates a similar effect, however in this experiment the redox probe is potassium ferricyanate. The graph shows the spectrophotometric determination of release of the encapsulated probe from polymeric beads as a function of time, at an alkaline pH of 9. As can be seen from the control values, when the pH is maintained at a mildly acidic pH of 5 the polymer does not dissolve and there is no increase in absorbance.

[0038] Figure 7 illustrates the production of current as a function of the ferrocene carboxylic acid release from the polymeric beads at different time points and at an alkaline test pH of 9 and a mildly acidic control pH of 5. The graph shows that at pH 9 more electro-active molecules were released from the polymer beads as a function of polymer dissolution at the elevated pH. This release is reflected in the increase of the detected current. No current increase was observed at pH 5.

REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- [US20100267166A \[0004\]](#)

Patentkrav

1. Apparat til kvantitativ analyse af en analyt i en prøve, omfattende

(i) en faste fase; og

(ii) en detektor,

5 hvor overfladen af den faste fase omfatter:

(a) en første position for prøvepræføring; og

(b) en anden position, fjernt fra den første position,

hvor et første molekyle der binder til analyten og er i stand til at frigive en
detekterbar species enten deponeres ved den første position eller tilsættes til

10 prøven før påføringen til den faste fase, og

hvor et andet molekyle der binder til analyten immobiliseres ved den anden
position, og

hvor et enzym co-lokaliseret immobiliseres med det immobiliserede molekyle ved
den anden position, og

15 hvor detektoren er anbragt i tæt nærhed til det immobiliserede molekyle ved den
anden position,

hvor et substrat til enzymet enten er normalt til stede i prøven, tilsættes til
prøven før påføringen til den faste fase, eller deponeres ved den første position på
den faste fase før prøvepræføringen, og

20 hvor interaktionen mellem enzymet og substratet resulterer i frigivelse af en
detekterbar species fra det første molekyle.

2. Apparat ifølge krav 1, yderligere omfattende organ til omdannelse af
detekteringen af species af detektoren til en koncentrationsværdi af analyt i

25 prøven.

3. Apparat ifølge et hvilket som helst af de foregående krav, hvor detektoren er
en elektrode og den detekterbare specie er en indkapslet redox-species.

4. Apparat ifølge et hvilket som helst af de foregående krav, hvor enzymet er urease og substratet er urea.

5. Apparat ifølge et hvilket som helst af de foregående krav, hvor den faste fase er en lateral strømningsmembran.

6. Fremgangsmåde til kvantitativ detektion af mål-molekyler i en substrat-indeholdende prøve, omfattende:

10 a) opløse et første opløseligt mærket bindingsmolekyle der er i stand til at frigive en detekterbar species og et andet opløseligt mærket bindingsmolekyle i prøven for at danne et kompleks;

b) påføre komplekset dannet i trin a) til en fast fase, hvor overfladen omfatter

i) en første position til påføring af komplekset, og

15 ii) en anden position, fjernt fra den første position

hvor et molekyle der binder til det andet bindingsmolekyle immobiliseres ved den anden position, hvor et enzym co-lokaliseret immobiliseres med det immobiliserede molekyle ved den anden position, og hvor en detektor er anbragt i tæt nærhed til det immobiliserede molekyle ved den anden position; og

20 c) detektere den detekterbare species ved detektoren mens komplekset transporteres til den anden position,

hvor detektering af disse species er proportional med målmolekyleindholdet af prøven.

25 7. Fremgangsmåde ifølge krav 6, hvor målmolekylet er et antigen.

8. Fremgangsmåde ifølge krav 6 eller krav 7, hvor det første og/eller andet bindingsmolekyle er antistoffer, fortrinsvis hvor det første antistof er mærket med en indkapslet redox-prøve, og fortrinsvis hvor det andet antistof er mærket med

biotin og molekylet der binder til det og immobiliseres ved den anden position er avidin.

9. Fremgangsmåde ifølge et hvilket som helst af kravene 6 til 8, hvor trin (c)

5 omfatter detektering af ændringen i strøm eller ladning passeret ved detektoren på grund af ændringen i lokal pH og resulterende frigivelse af redox-prøven, fortrinsvis hvor strømmen som stammer fra oxidation eller reduktion af redox-prøven er proportional med antigenindholdet af prøven.

10 **10.** Fremgangsmåde ifølge et hvilket som helst af kravene 6 til 9, hvor detektoren er en elektrode fortrinsvis hvor elektroden er en skærmprintet elektrode.

11. Fremgangsmåde ifølge et hvilket som helst af kravene 6 til 10, hvor redox-prøven er indkapslet i en polymer.

15 **12.** Fremgangsmåde ifølge krav 11, hvor polymeren er en enterisk coating der opløses under alkaliske betingelser.

13. Fremgangsmåde ifølge krav 11, hvor polymeren kvælder i sure eller alkaliske

20 betingelser.

14. Fremgangsmåde ifølge et hvilket som helst af kravene 6 til 13, hvor prøven er en urea-indeholdende prøve, og fortrinsvis hvor enzymet er urease.

25 **15.** Anvendelse af et apparat ifølge et hvilket som helst af kravene 1 til 5 i fremgangsmåden ifølge et hvilket som helst af kravene 6 til 14.

DRAWINGS




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6




Figure 7